ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells

Li,Xiaoning; Guo,Yumeng; Xing,Zihan; Gong,Tao; Yang,Lijun; Yang,Tao; Chang,Bingmei; Wang,Xiaoxia; Yu,Baofeng; Guo,Rui

doi:10.3892/or.2024.8781

ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells

Authors:
- Xiaoning Li
- Yumeng Guo
- Zihan Xing
- Tao Gong
- Lijun Yang
- Tao Yang
- Bingmei Chang
- Xiaoxia Wang
- Baofeng Yu
- Rui Guo
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Hematology, Linfen Central Hospital, Linfen, Shanxi 041099, P.R. China, Department of Pharmacology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: July 23, 2024 https://doi.org/10.3892/or.2024.8781
Article Number: 122
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is a gynecological malignant tumor with the highest mortality rate, and chemotherapy resistance seriously affects patient therapeutic outcomes. It has been shown that the high expression of anti‑apoptotic proteins Bcl‑2 and Bcl‑xL is closely related to ovarian cancer chemotherapy resistance. Therefore, reducing Bcl‑2 and Bcl‑xL expression levels may be essential for reversing drug resistance in ovarian cancer. ABT‑737 is a BH3‑only protein mimetic, which can effectively inhibit the expression of the anti‑apoptotic proteins Bcl‑xL and Bcl‑2. Although it has been shown that ABT‑737 can increase the sensitivity of ovarian cancer cells to cisplatin, the specific molecular mechanism remains unclear and requires further investigation. In the present study, the results revealed that ABT‑737 can significantly increase the activation levels of JNK and ASK1 induced by cisplatin in A2780/DDP cells, which are cisplatin‑resistant ovarian cancer cells. Inhibition of the JNK and ASK1 pathway could significantly reduce cisplatin cytotoxicity increased by ABT‑737 in A2780/DDP cells, while inhibiting the ASK1 pathway could reduce JNK activation. In addition, it was further determined that ABT‑737 could increase reactive oxygen species (ROS) levels in A2780/DDP cells induced by cisplatin. Furthermore, the inhibition of ROS could significantly reduce JNK and ASK1 activation and ABT‑737‑mediated increased cisplatin cytotoxicity in A2780/DDP cells. Overall, the current data identified that activation of the ROS‑ASK1‑JNK signaling axis plays an essential role in the ability of ABT‑737 to increase cisplatin sensitivity in A2780/DDP cells. Therefore, upregulation the ROS‑ASK1‑JNK signaling axis is a potentially novel molecular mechanism by which ABT‑737 can enhance cisplatin sensitivity of ovarian cancer cells. In addition, the present research can also provide new therapeutic strategies and new therapeutic targets for patients with cisplatin‑resistant ovarian cancer with high Bcl‑2/Bcl‑xL expression patterns.

View Figures

View References

1	Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, et al: European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 33:276–287. 2022. View Article : Google Scholar : PubMed/NCBI
2	Zhao L, Guo H, Chen X, Zhang W, He Q, Ding L and Yang B: Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. Eur J Pharmacol. 927:1750712022. View Article : Google Scholar : PubMed/NCBI
3	Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G and Fagotti A: Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin Cancer Biol. 77:144–166. 2021. View Article : Google Scholar : PubMed/NCBI
4	Song M, Cui M and Liu K: Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 232:1142052022. View Article : Google Scholar : PubMed/NCBI
5	McGlorthan L, Paucarmayta A, Casablanca Y, Maxwell GL and Syed V: Progesterone induces apoptosis by activation of caspase-8 and calcitriol via activation of caspase-9 pathways in ovarian and endometrial cancer cells in vitro. Apoptosis. 26:184–194. 2021. View Article : Google Scholar : PubMed/NCBI
6	Ni M, Zhou J, Zhu Z, Xu Q, Yin Z, Wang Y, Zheng Z and Zhao H: Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe²⁺ accumulation. Phytomedicine. 112:1547012023. View Article : Google Scholar : PubMed/NCBI
7	Ferrara M, Pecorino B, D'Agate MG, Angelico G, Capoluongo ED, Malapelle U, Pepe F, Scollo P and Mereu L: Uterine tumours resembling ovarian sex-cord tumors: A case report and review of the literature. J Clin Med. 12:71312023. View Article : Google Scholar : PubMed/NCBI
8	Ortiz M, Wabel E, Mitchell K and Horibata S: Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 5:304–316. 2022.PubMed/NCBI
9	Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, et al: Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Mol Cancer Res. 17:2281–2293. 2019. View Article : Google Scholar : PubMed/NCBI
10	Yuan J, Lan H, Jiang X, Zeng D and Xiao S: Bcl-2 family: Novel insight into individualized therapy for ovarian cancer (review). Int J Mol Med. 46:1255–1265. 2020.PubMed/NCBI
11	Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY and Liu JR: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol. 96:287–295. 2005. View Article : Google Scholar : PubMed/NCBI
12	Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ and Belmont LD: Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther. 11:1026–1035. 2012. View Article : Google Scholar : PubMed/NCBI
13	Xu L, Xie Q, Qi L, Wang C, Xu N, Liu W, Yu Y, Li S and Xu Y: Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Oncol Rep. 39:985–992. 2018.PubMed/NCBI
14	Maji S, Panda S, Samal SK, Shriwas O, Rath R, Pellecchia M, Emdad L, Das SK, Fisher PB and Dash R: Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res. 137:37–75. 2018. View Article : Google Scholar : PubMed/NCBI
15	Guo T, Gu C, Li B and Xu C: Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain. Aging (Albany NY). 13:19750–19759. 2021. View Article : Google Scholar : PubMed/NCBI
16	Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK and Johnstone RW: Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 113:1982–1991. 2009. View Article : Google Scholar : PubMed/NCBI
17	Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ and Pastan I: Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma. 52 (Suppl 2):S79–S81. 2011. View Article : Google Scholar
18	Fan Z, Yu H, Cui N, Kong X, Liu X, Chang Y, Wu Y, Sun L and Wang G: ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics. Exp Cell Res. 335:68–81. 2015. View Article : Google Scholar : PubMed/NCBI
19	Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X, Yu C, Jiang X, Xu Y and Su L: ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol. 49:2507–2519. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ni Z, Wang B, Dai X, Ding W, Yang T, Li X, Lewin S, Xu L, Lian J and He F: HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway. Free Radic Biol Med. 70:194–203. 2014. View Article : Google Scholar : PubMed/NCBI
21	Moloney JN and Cotter TG: ROS signalling in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018. View Article : Google Scholar : PubMed/NCBI
22	Huang M, Li X, Jia S, Liu S, Fu L, Jiang X and Yang M: Bisphenol AF induces apoptosis via estrogen receptor beta (ERβ) and ROS-ASK1-JNK MAPK pathway in human granulosa cell line KGN. Environ Pollut. 270:1160512021. View Article : Google Scholar : PubMed/NCBI
23	Keuling AM, Andrew SE and Tron VA: Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: Novel regulation of PUMA. Pigment Cell Melanoma Res. 23:430–440. 2010. View Article : Google Scholar : PubMed/NCBI
24	Will B, Siddiqi T, Jordà MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG and Kobayashi S: Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 115:2901–2909. 2010. View Article : Google Scholar : PubMed/NCBI
25	Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P and Grant S: Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther. 8:808–819. 2009. View Article : Google Scholar : PubMed/NCBI
26	Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, et al: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 26:778–787. 2012. View Article : Google Scholar : PubMed/NCBI
27	Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer. 47:1585–1594. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhang H, Kong X, Kang J, Su J, Li Y, Zhong J and Sun L: Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 110:376–388. 2009. View Article : Google Scholar : PubMed/NCBI
29	Zhang C, Shi J, Mao SY, Xu YS, Zhang D, Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, et al: Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737. J Cell Mol Med. 19:408–417. 2015. View Article : Google Scholar : PubMed/NCBI
30	Kim EK and Choi EJ: Compromised MAPK signaling in human diseases: An update. Arch Toxicol. 89:867–882. 2015. View Article : Google Scholar : PubMed/NCBI
31	Dong D, Dong Y, Fu J, Lu S, Yuan C, Xia M and Sun L: Bcl2 inhibitor ABT737 reverses the Warburg effect via the Sirt3-HIF1α axis to promote oxidative stress-induced apoptosis in ovarian cancer cells. Life Sci. 255:1178462020. View Article : Google Scholar : PubMed/NCBI
32	Morita K, Saitoh M, Tobiume K, Matsuura H, Enomoto S, Nishitoh H and Ichijo H: Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO J. 20:6028–6036. 2001. View Article : Google Scholar : PubMed/NCBI
33	Li H, Yang Q, Huang Z, Liang C, Zhang DH, Shi HT, Du JQ, Du BB and Zhang YZ: Dual-specificity phosphatase 12 attenuates oxidative stress injury and apoptosis in diabetic cardiomyopathy via the ASK1-JNK/p38 signaling pathway. Free Radic Biol Med. 192:13–24. 2022. View Article : Google Scholar : PubMed/NCBI
34	Konstantinopoulos PA and Matulonis UA: Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 4:1239–1257. 2023. View Article : Google Scholar : PubMed/NCBI
35	Zuo Y, Zheng W, Liu J, Tang Q, Wang SS and Yang XS: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 67:93–101. 2020. View Article : Google Scholar : PubMed/NCBI
36	Moghbeli M: MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells. J Ovarian Res. 14:1272021. View Article : Google Scholar : PubMed/NCBI
37	Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB and Richardson A: The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 13:7191–7198. 2007. View Article : Google Scholar : PubMed/NCBI
38	Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, et al: Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex vivo experiment in human serous ovarian carcinoma. Int J Cancer. 136:E340–E350. 2015. View Article : Google Scholar : PubMed/NCBI
39	Lomovsky A, Baburina Y, Odinokova I, Kobyakova M, Evstratova Y, Sotnikova L, Krestinin R and Krestinina O: Melatonin can modulate the effect of navitoclax (ABT-737) in HL-60 cells. Antioxidants (Basel). 9:11432020. View Article : Google Scholar : PubMed/NCBI
40	Lee S, Rauch J and Kolch W: Targeting MAPK signaling in cancer: Mechanisms of drug resistance and sensitivity. Int J Mol Sci. 21:11022020. View Article : Google Scholar : PubMed/NCBI
41	Adamová B, Říhová K, Pokludová J, Beneš P, Šmarda J and Navrátilová J: Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells. J Cell Mol Med. 27:76–88. 2023. View Article : Google Scholar : PubMed/NCBI
42	Zheng R, You Z, Jia J, Lin S, Han S, Liu A, Long H and Wang S: Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells. Mol Med Rep. 13:1570–1576. 2016. View Article : Google Scholar : PubMed/NCBI
43	Chen Q, Hou Y, Li D, Ding Z, Xu X, Hao B, Xia Q, Li M and Fan L: Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway. Ann Transl Med. 10:4852022. View Article : Google Scholar : PubMed/NCBI
44	Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J and Sun L: ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 53:1055–1068. 2018.PubMed/NCBI
45	Sha JF, Xie QM, Chen N, Song SM, Ruan Y, Zhao CC, Liu Q, Shi RH, Jiang XQ, Fei GH and Wu HM: TLR2-hif1α-mediated glycolysis contributes to pyroptosis and oxidative stress in allergic airway inflammation. Free Radic Biol Med. 200:102–116. 2023. View Article : Google Scholar : PubMed/NCBI
46	Zhang L, Wang Z, Lu T, Meng L, Luo Y, Fu X and Hou Y: Mitochondrial Ca²⁺ overload leads to mitochondrial oxidative stress and delayed meiotic resumption in mouse oocytes. Front Cell Dev Biol. 8:5808762020. View Article : Google Scholar : PubMed/NCBI
47	Pecorino B, Scibilia G, Ferrara M, Di Stefano AB, D'Agate MG, Giambanco L and Scollo P: Prognostic factors and surgical treatment in vulvar carcinoma: Single center experience. J Obstet Gynaecol Res. 46:1871–1878. 2020. View Article : Google Scholar : PubMed/NCBI
48	Li M, Wang D, He J, Chen L and Li H: Bcl-X_L: A multifunctional anti-apoptotic protein. Pharmacol Res. 151:1045472020. View Article : Google Scholar : PubMed/NCBI